| |
All participants n (%)
|
BPH-related factors
|
ED -elated factors
|
|---|
|
Prostate size
|
IPSS score
|
BPH medication use at baseline
|
BPH composite measure
|
ED medication use at baseline ED medication use at baseline
|
ED medication or device use at follow-up
|
|---|
|
< 40 g
|
≥ 40 g
|
< 8
|
≥ 8
|
No
|
Yes
|
No BPH
|
Any BPH
|
No
|
Yes
|
No
|
Yes
|
|---|
|
Sexual function 5 weeks post-surgery (n = 357)
|
|
Impaired
| | | | | | | | | | | | | |
|
N
|
262 (79.0)
| | | | | | | | | | | | |
|
OR 95% CI
| | | | | | | | | | | | | |
|
Maintained
| | | | | | | | | | | | | |
|
N
|
69 (19.3)
| | | | | | | | | | | | |
|
OR 95% CI
| | | | | | | | | | | | | |
|
Improved
| | | | | | | | | | | | | |
|
N
|
6 (1.7)
| | | | | | | | | | | | |
|
OR 95% CI
| | | | | | | | | | | | | |
|
Sexual function 12 months post-surgery (n = 332)
|
|
Impaired
| | | | | | | | | | | | | |
|
N
|
229 (69.0)
|
76
|
96
|
73
|
73
|
205
|
24
|
91
|
138
|
217
|
12
|
70
|
154
|
|
OR 95% CI
| |
Reference
|
Reference
|
Reference
|
Reference
|
Reference
|
Reference
|
|
Maintained
| | | | | | | | | | | | | |
|
N
|
92 (27.7)
|
39
|
28
|
35
|
28
|
80
|
12
|
40
|
52
|
88
|
4
|
40
|
48
|
|
OR 95% CI
| |
0.6 (0.3 to 1.0)
|
0.8 (0.4 to 1.4)
|
1.3 (0.6 to 2.7)
|
0.8 (0.5 to 1.4)
|
0.8 (0.3 to 2.6)
|
0.5 (0.3 to 0.9)
|
|
Improved
| | | | | | | | | | | | | |
|
N
|
11 (3.3)
|
3
|
6
|
4
|
4
|
8
|
3
|
2
|
9
|
11
|
0
|
2
|
5
|
|
OR 95% CI
| |
1.6 (0.4 to 6.5)
|
1.0 (0.2 to 4.2)
|
3.2 (0.8 to 13)
|
3.0 (0.6 to 14)
|
NE
|
1.1 (0.2 to 6.0)
|
|
Sexual bother 5 weeks post-surgery (n = 354)
|
|
Impaired
| | | | | | | | | | | | | |
|
N
|
259 (73.2)
|
94
|
96
|
86
|
77
|
232
|
27
|
110
|
149
|
243
|
16
|
117
|
131
|
|
OR 95% CI
| |
Reference
|
Reference
|
Reference
|
Reference
|
Reference
|
Reference
|
|
Maintained
| | | | | | | | | | | | | |
|
N
|
69 (19.5)
|
27
|
27
|
27
|
22
|
61
|
8
|
30
|
39
|
69
|
0
|
36
|
24
|
|
OR 95% CI
| |
1.0 (0.5 to 1.8)
|
0.9 (0.5 to 1.7)
|
1.1 (0.5 to 2.6)
|
1.0 (0.6 to 1.6)
|
NE
|
0.6 (0.3 to 1.1)
|
|
Improved
| | | | | | | | | | | | | |
|
N
|
26 (7.3)
|
6
|
11
|
8
|
11
|
16
|
10
|
3
|
23
|
24
|
2
|
16
|
10
|
|
OR 95% CI
| |
1.8 (0.6 to 5.1)
|
1.5 (0.6 to 4.0)
|
5.4 (2.2 to 13.0)
|
5.7 (1.7 to 19.3)
|
1.3 (0.3 to 5.8)
|
0.6 (0.2 to 1.3)
|
|
Sexual bother 12 months post-surgery (n = 329)
|
|
Impaired
| | | | | | | | | | | | | |
|
N
|
229 (69.6)
|
78
|
89
|
81
|
67
|
206
|
23
|
98
|
131
|
216
|
13
|
68
|
157
|
|
OR 95% CI
| |
Reference
|
Reference
|
Reference
|
Reference
|
Reference
|
Reference
|
|
Maintained
| | | | | | | | | | | | | |
|
N
|
65 (19.8)
|
28
|
23
|
22
|
19
|
56
|
9
|
28
|
37
|
62
|
3
|
27
|
34
|
|
OR 95% CI
| |
0.7 (0.4 to 1.4)
|
1.0 (0.5 to 2.1)
|
1.4 (0.6 to 3.3)
|
1.0 (0.6 to 1.7)
|
0.8 (0.2 to 2.9)
|
0.5 (0.3 to 1.0)
|
|
Improved
| | | | | | | | | | | | | |
|
N
|
35 (10.6)
|
8
|
19
|
11
|
15
|
30
|
5
|
7
|
28
|
35
|
0
|
13
|
16
|
|
OR 95% CI
| |
2.1 (0.9 to 5.0)
|
1.6 (0.7 to 3.8)
|
1.5 (0.5 to 4.2)
|
3.0 (1.2 to 7.1)
|
NE
|
0.5 (0.2 to 1.2)
|
- BPH benign prostatic hyperplasia, CI confidence interval, ED erectile dysfunction, IPSS International Prostate Symptom Score, OR odds ratio, NE not estimable
- EPIC-50 measured urinary and sexual outcome trajectories were defined as impaired (negative change greater than the upper bound of minimally important difference), maintained, and improved (positive change greater than the upper bound of minimally important difference). Sexual function, sexual bother: impaired (change < 12); maintained (-12 ≤ change ≤ 12); improved (change ≥ 12)
